Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Announces Annual General Meeting Voting Results

T.RVX

TSX Exchange Symbol:  RVX

CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual meeting of shareholders held on October 8, 2014, each of the five nominees proposed as a director and listed in its management information circular dated August 25, 2014 (the "Information Circular") were elected as directors.  Proxy voting results for each nominee are set out below:


Votes For

Votes Withheld

% For

% Withheld

Donald J. McCaffrey

19,598,577

272,713

(98.63%)

(1.37%)

Peter Johann

19,735,454

135,836

(99.32%)

(0.68%)

Kelly McNeill

19,598,354

272,936

(98.63%)

(1.37%)

Kenneth Zuerblis

19,745,389

125,901

(99.37%)

(0.63%)

Eldon Smith

19,618,789

252,501

(98.73%)

(1.27%)

 

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-1.  RVX-208 is a first in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease.  RVX-208 is the first BET bromodomain inhibitor in clinical trials.  Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX).  For further information, please visit www.resverlogix.com.  We can be followed on our blog at http://www.resverlogix.com/blog.

Company Contacts:




Donald J. McCaffrey              

Sarah Zapotichny

President and CEO                

Director, Investor Relations

Resverlogix Corp.                    

Resverlogix Corp.

Phone:  403-254-9252             

Phone:  403-254-9252

Email:  don@resverlogix.com       

Email:  sarah@resverlogix.com

 

SOURCE Resverlogix Corp.

Copyright CNW Group 2014